Source link : https://www.newshealth.biz/health-news/novel-btk-inhibitor-succeeds-in-heavily-pretreated-immune-thrombocytopenia/
SAN DIEGO — Treatment with an investigational oral inhibitor of Bruton’s tyrosine kinase (BTK) was safe and boosted platelet counts in heavily pretreated patients with immune thrombocytopenia (ITP), a phase III trial showed. In the so-called LUNA 3 study, 23% of patients assigned to rilzabrutinib achieved a durable platelet response at week 25 without the […]
Author : News Health
Publish date : 2024-12-08 20:02:49
Copyright for syndicated content belongs to the linked Source.